Choroidal neovascularization (CNV) is the abnormal growth of blood vessels beneath the retina, a leading cause of vision loss in conditions such as age-related macular degeneration (AMD) and pathologic myopia. The global choroidal neovascularization market is expanding as the aging population grows and treatment options improve.

The choroidal neovascularization market is driven by rising AMD prevalence, increasing awareness of vision-threatening conditions, and advances in anti-VEGF therapies. These injectable drugs have transformed CNV management, preserving vision in many patients. As more patients are diagnosed and treated, demand for therapies and diagnostics grows.

Innovation is a key driver. Longer-acting anti-VEGF agents, novel delivery systems, and combination therapies are being developed to reduce treatment burden and improve outcomes. Diagnostic imaging, including OCT and angiography, supports early detection and monitoring.

Challenges include high treatment costs, frequent injections, and access barriers in some regions. However, as populations age and new therapies emerge, the choroidal neovascularization market is expected to grow steadily.

People Also Ask

• What is choroidal neovascularization? It is abnormal blood vessel growth under the retina, often linked to macular degeneration and causing vision loss.

• How is CNV treated? Anti-VEGF injections are the standard treatment, sometimes combined with other therapies.

Tags: #ChoroidalNeovascularization #MacularDegeneration #AntiVEGF #Ophthalmology #VisionCare #Retina